Clinical Trial

A Study to Explore the Safety, Tolerability, Efficacy, and Pharmacokinetics of LT-002-158 Tablets in Chinese Adult Subjects With Atopic Dermatitis

Not Yet Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated April 17, 2025 (before its estimated October 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
This study is an Ic/II phase clinical trial conducted in Chinese subjects with moderate to severe atopic dermatitis. The phase Ic study is a randomized, open label, parallel group design, mainly evaluating the safety and tolerability of LT-002-158 tablets in subjects with moderate to severe atopic dermatitis. The phase II study is a randomized, double-blind, placebo-controlled, parallel group design, with a single arm design for extended treatment, mainly exploring the efficacy of LT-002-158 tablets in the treatment of moderate to severe atopic dermatitis subjects.
Trial Details
NCT Number NCT06931990
Lead Sponsor Leadingtac Pharmaceutical (Shaoxing) Co., Ltd.
Conditions Atopic Dermatitis (AD)
Enrollment 24 participants
Start Date 2025-04-15
Primary Completion 2025-10-30 (estimated)
Study Completion 2025-12-30 (estimated)
Updated on ClinicalTrials.gov 2025-04-17